July 2, 2024
Authored and Edited by Luke H. MacDonald, Ph.D.; Erik R. Puknys; Arthur Harris†
In Insulet Corp. v. EOFlow Co., Ltd., No. 2024-1137 (Fed. Cir. June 17, 2024), the Federal Circuit vacated a preliminary injunction for lack of evidence showing a likelihood of success and for ignoring aspects of the preliminary injunction analysis.
Insulet and EOFlow make wearable insulin pump patches. Four former Insulet employees joined EOFlow in 2017. EOFlow subsequently received approval to sell pumps abroad and, in 2023, engaged in acquisition talks with Medtronic. Insulet sued EOFlow in early 2023 for trade secret misappropriation and sought an injunction against EOFlow’s products and a restraining order to prevent technical communications with Medtronic.
In August 2023, the district court restrained EOFlow from disclosing technical information, and in October granted a “sweeping” preliminary injunction preventing manufacturing, selling, or marketing of any product designed, developed, or manufactured using Insulet’s trade secrets. The district court relied heavily on its findings that the former Insulet employees had retained confidential documents and that EOFlow’s potential acquisition caused Insulet irreparable harm. The court defined the misappropriated trade secrets as “any and all Confidential Information of Insulet,” including technical documents not marked confidential.
The Federal Circuit vacated and remanded. It first found the district court ignored evidence that the statute of limitations may have passed. It further held the injunction overbroad for failing to identify specific trade secrets or consider whether Insulet had protected them. It next found the district court overlooked information that the alleged trade secrets could be reverse-engineered from public disclosures and the Insulet product itself. Additionally, the Court held the district court conflated Insulet’s likelihood of success with irreparable harm to EOFlow, relied on conjecture when assessing that harm, and failed to analyze the injunction’s impact on the public. The Court noted it had not found Insulet cannot ultimately succeed, but only that Insulet had not proven the elements required to obtain a preliminary injunction.
†Arthur Harris is a Summer Associate at Finnegan.
Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Federal Circuit IP Blog
Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay
May 14, 2026
Federal Circuit IP Blog
When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case
May 14, 2026
INCONTESTABLE® Blog
Netflix Prevails in Copyright Infringement Suit Regarding Tiger King
May 14, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.